• A Study Evaluating the Value of 68Ga-NOTA-RCCB6 PET Imaging for Targeting CD70 in the Clinical Staging, Therapeutic Evaluation, and Restaging of Renal Cell Carcinoma, and Comparing It with 68Ga-PSMA PET/CT Imaging

  NCT06769893

  RecruitingInterventionalNot ApplicableUpdated Jan 10, 2025
• Evaluation of 68Ga-PSMA PET-CT in the Initial Staging of Advanced Renal Cell Carcinomas - A Prospective, Multicentre, Open-label Study

  NCT07624578

  WithdrawnInterventionalNot ApplicableUpdated Jun 3, 2026
• Imaging Studies of Kidney Cancer Using 18F-VM4-037

  NCT01712685

  TerminatedInterventionalPhase 2Updated Jan 11, 2017
• Diagnosis of Renal Cell Carcinoma on 68Ga-PSMA PET-CT and Radioligand Therapy With 177Lu-EB-PSMA-617

  NCT05170555

  Unknown statusInterventionalNot ApplicableUpdated Dec 28, 2021
• 68Ga-RM2 Compared to 68Ga-PSMA-617 PET/CT for Prostate Cancer Imaging According to Various Metastatic Risks

  NCT03604757

  CompletedInterventionalPhase 2Updated May 14, 2026
• [18F]PT2385 PET/CT in Patients With Renal Cell Carcinoma

  NCT04989959

  RecruitingInterventionalPhase 1Updated Dec 4, 2025

ClinicalTrials.gov ID

NCT07346404

Lead Sponsor

Assistance Publique - Hôpitaux de ParisOTHER

Overall Status

Not yet recruiting

Study Type

Interventional

Phase

Phase 2

Enrollment

50Estimated

Last Update Posted

Jan 16, 2026Actual

Start Date

Jan 1, 2026Estimated

Primary Completion Date

Jan 1, 2028Estimated

Completion Date

Jan 1, 2028Estimated

Official Title

Dynamic 82-Rb Positron Emission Tomography (PET) for the Grading of KIDney Carcinoma

Brief Summary

This is a pilot prospective longitudinal monocentric, non-comparative, nonrandomised, and non-controlled open study.

is to test whether the intensity of 82-Rb uptake on PET acquisitions is associated to the aggressiveness of RCC on histology (ISUP grades), i.e., to successfully identify high-grade (ISUP grades 3 and 4) vs. lowgrade (ISUP grades 1 and 2) RCC.

Detailed Description

Tumoral vascularization is an important prognostic marker in renal cell carcinomas (RCC). The evaluation of RCC is often complex before surgery as only a small peripheral segment of the tumor is obtained with biopsy and tend to underestimate the aggressiveness and grade of RCC. Accurate noninvasive evaluation of the aggressiveness of RCC could improve the characterization of tumors before surgery and help guide patient management. Radiolabeled water has demonstrated its interest for the quantification of the vascularization of renal tumors in Positron Emission Tomography (PET). The synthesis of radiolabeled water requires, however, an on-site cyclotron, which is available only in a limited number of hospitals. 82-Rb, a potassium analog and positron-emitting radiotracer, is taken up by myocardial and renal cells. 82-Rb has been used for more than 15 years in North America for the quantification of myocardial perfusion with PET. The solution of 82-Rb chloride is obtained from 82-Sr / 82-Rb radiopharmaceutical generators which have recently obtained a marketing authorization in Europe. These generators can be installed in nuclear medicine departments in hospitals. Myocardial perfusion flow can be precisely quantified by modelling tissue uptake of the tracer on dynamic acquisitions obtained during the intravenous administration of 82-Rb chloride. Our hypothesis is that 82-Rb uptake profile could help grade noninvasively the aggressiveness of renal tumors.

• Renal Cell Carcinoma

• 82-Rb injection

Ages Eligible for Study

Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Eligibility Criteria

Inclusion Criteria:

• Age ≥ 18 years old
• Signed written informed consent
• French Social Security affiliation
• Patients with high suspicion of or confirmed RCC requiring surgical resection
• Kidney tumor diameter between 2 cm and 7 cm with clear cell imaging feature (hyper vascular lesion with contrast-enhancement similar to the renal cortex on CTA)
• Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures

Exclusion Criteria:

• Pregnant or breastfeeding women
• Patient under legal protection (guardianship)
• Contraindication to the PET-CT
• Contraindication to the injection of 82-Rb
• Participation in another interventional study involving human participants or being in the exclusion period at the end of a previous study involving human participants, if applicable
• Patient on SMA (state medical aid)
• Unilateral renal agenesis
• Multicystic renal dysplasia
• Hereditary forms of RCC as VHL, MET, FH and FLCN
• Bosniak 3 cysts
• Hypovascular lesions with enhancement inferior to the renal cortex in corticomedullary-phase images on CTA
• Exclusion of clear renal cell adenocarcinoma on biopsy
• Kidney tumors with high suspicion of extra-renal extension (cT3b, cT3c, cN+ or M+).

Primary Purpose

Diagnostic

Allocation

N/A

Interventional Model

Single Group Assignment

Masking

None (Open Label)

Lead Sponsor

Assistance Publique - Hôpitaux de ParisOTHER

Collaborators

Naogen PharmaUNKNOWN

fabien.hyafil@aphp.fr+33 1 56 09 39 97